Reliance Industries reported consolidated revenue growth of 17.7% for Q2 FY27, led by its Pharmaceutical division, which contributed 31.8% of the total. Operating margin held at 7.3%, a few basis points below the previous quarter as higher logistics and wage costs offset operating leverage.
Balance-sheet metrics remain comfortable. Net debt to earnings stood at 0.8 times, and the company retired $402 million of high-cost borrowings during the quarter. Credit analysts say the improvement leaves room to fund the expansion without equity dilution.
The numbers
Risks were not ignored. Executives flagged input-cost volatility, potential delays in environmental clearances for the new plant and the possibility of tougher competition from lower-priced imports. They said a pricing-pass-through mechanism covers about 60 percent of exposure.
A new long-term agreement with Sun Pharma anchors a portion of the expansion. The deal covers multi-year supply at index-linked pricing, with volume commitments that provide a floor, and includes a joint development programme for higher-specification products with better margins.
By the numbers
Environmental, social and governance targets also featured. The company reiterated its goal to reduce emissions intensity by a third by 2032, and disclosed that 31.8% of electricity at its main sites now comes from renewable sources under long-term contracts.
“Visibility is worth more than growth. We can plan investments when we can see 14 months ahead.”
Expansion and capital allocation
Analysts were broadly constructive. Of 18 brokerages covering the stock, 12 maintain buy ratings, with target prices implying about 31.8% upside. The more cautious voices pointed to a valuation premium and the execution risk inherent in a large expansion programme.
Source: IGEN Intelligence analysis of un comtrade data. Illustrative mock data.
On the post-results call, management said the order book now stands at $1.3 billion, equivalent to roughly 14 months of revenue, with about a third from export customers in Germany and Saudi Arabia. The chief financial officer described visibility as the best in five years.
| Segment | Revenue | YoY | Margin |
|---|---|---|---|
| Pharmaceutical (core) | $411M | +5.5% | 10.9% |
| Exports | $153M | +18.4% | 15.1% |
| Domestic retail | $402M | -0.3% | 18.5% |
| Services | $430M | +14% | 12.7% |
| Other | $239M | +11.9% | 21.9% |
Customers, contracts and exports
The company also announced a new facility near Pipavav, designed to add about 507 tonnes of annual capacity and create roughly 1,200 jobs. Construction begins next quarter, and first production is targeted within 20 months. The plant will be built to meet European environmental standards.
Timeline of key events
- Results announced
Revenue up 17.7%; margin steady at 7.3%.
- Capex raised
Guidance moves to $1.3 billion to fund automation and debottlenecking.
- Supply pact signed
Multi-year agreement with Sun Pharma at index-linked pricing.
- Groundbreaking
Construction at the new facility near Pipavav begins.
- First production
Targeted within 20 months of groundbreaking.
Capital expenditure guidance was raised to $1.3 billion for the fiscal year, from $402 million previously. Management said the increase reflects accelerated spending on automation and on debottlenecking existing lines, which it expects to deliver 7.3% more output without additional land.
Expert commentary
“The pact is not just volume; it is a joint roadmap for higher-value products.”
“Buyers are paying a premium for certainty. Suppliers who can document, deliver and communicate will capture it.”
“Firms that treat this as a compliance exercise will keep up. Firms that treat it as a design problem will pull ahead.”
Risks and analyst view
Employees and communities are part of the plan: a skills academy near the new site will train 2,000 technicians over three years, funded jointly with the state government. Management said local hiring is a condition of the incentives it has received.
What it means for you
Order visibility and a manageable balance sheet support the story; track execution on the new plant and margin pass-through.
Expansion will lift procurement; engage early on qualification for the new lines.
Longer-term agreements offer price stability in exchange for volume commitments; compare index-linked terms carefully.
About 1,200 direct roles and a technician academy are planned near Pipavav; applications open with the state skills portal.
Companies and leaders in this story
Frequently asked questions
Sources
- UN Comtrade: Bilateral trade flows by HS code
- Reserve Bank of India: Exchange-rate and trade-credit bulletins
- Industry association surveys: Member-level compliance and sentiment data
- Port authority statistics: Container volumes, dwell times and berth productivity
Mock content for demonstration. Names, figures and quotes are illustrative and not real reporting.
